Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
Mineralys Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $14.48, Mineralys Therapeutics, Inc. trades at 2.6x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -63.3%, return on invested capital of -64.7% and a free cash flow yield of -11.9%. On the balance sheet: a debt-to-equity ratio of 0.20 and a current ratio of 11.83. Over the past 52 weeks the share price ranged from $14.30 to $45.00, with a beta of 0.69.
Mineralys Therapeutics, Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 7 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Mineralys Therapeutics, Inc. (MLYS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 4.97% / 30% · (Cash+Inv) / Mkt Cap (36m) 31.6% / 30% · Interest income / Revenue 594700000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 4.97% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 31.6% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 594700000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 4.97% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 31.6% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 594700000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 7.50% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 99.1% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 594700000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 15.6% / 33.33% · (Cash+ST Inv) / Total Assets 99.1% / 33.33% · (Cash+Recv) / Total Assets 99.1% / 33.33% · Interest income / Revenue 594700000.0% / 5% | Fail |
No. As of September 2026, Mineralys Therapeutics, Inc. (MLYS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Mineralys Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 594700000.0% of each dividend: Mineralys Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.